Centessa IPO Presentation Deck

Lixivaptan: Status and Competition STATUS & UPCOMING MILESTONES The ALERT Study The ACTION Study Mid-to-late 2021 Early-to-mid 2022 Ongoing clinical study in up to 50 ADPKD patients who previously discontinued tolvaptan due to liver toxicity • Aims to assess lixivaptan's safety profile in patient population enriched for DILI • Patient screening and recruitment underway Preparing to initiate global, pivotal Phase 3 clinical study in ADPKD patients Preliminary data from the ALERT study Start of Phase 3 pivotal clinical trial COMPETITIVE LANDSCAPE Tolvaptan, vasopressin V2 inhibitor: Marketed (Otsuka,~Sep 2026 patent expiry) Venglustat, glucosylceramide synthase inhibitor: Phase 3 (Sanofi) Bardoxolone, oral Nrf2 activator: Phase 3 (Reata Pharmaceuticals) PALLADIO BIOSCIENCES CENTESSA 16

View entire presentation